Clinical Trials Browser

Suspended × Breast × 90 days × Clear all

NCT06538389 2026-04-15

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

Phase 2 Suspended

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT07140965 2026-04-14

The Impact of Surgeon-Interpreted Intraoperative Margin Assessment During Breast Conserving Surgery on Postoperative Treatment

Breast Neoplasms

NCT04955808 2026-04-13

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

BreastGastrointestinalGenitourinaryPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Multiple Myeloma, Prostatic Neoplasms

NCT05111561 2026-04-13

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Phase 1 Suspended

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05751668 2026-04-07

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

Phase 2 Suspended

Breast Neoplasms

NCT05547347 2026-03-31

Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8

NCT03737695 2026-03-18

Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer

Breast Neoplasms

NCT03987555 2026-03-18

Paclitaxel Therapeutic Drug Monitoring in Cancer Patients

BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vulvar Neoplasms

NCT05656131 2026-03-17

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Phase 2 Suspended

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

NCT03077841 2026-03-05

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

Phase 2/3 Suspended

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT07136493 2026-03-05

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

Phase NA Suspended

Triple Negative Breast Neoplasms

NCT06671912 2026-03-04

LoTam

Phase 3 Suspended

Breast Carcinoma In Situ

NCT02993068 2026-02-19

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Phase NA Suspended

Triple Negative Breast Neoplasms

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors